Lilly Acquires Centessa, Adds Orexin Receptor 2 Agonists for Narcolepsy Pipeline
LLY•LLY•LLY•LLY•Lilly has completed its acquisition of Centessa Pharmaceuticals, adding clinical-stage orexin receptor 2 agonists targeting narcolepsy and other sleep-wake disorders to its pipeline. The deal positions Lilly to advance novel brain health therapies and leverage Centessa’s depth in sleep disease research with accelerated development plans.
On June 24 2026, Lilly finalized its acquisition of Centessa Pharmaceuticals, integrating the clinical-stage company into its neuroscience division.
Centessa’s lead programs focus on orexin receptor 2 agonists designed to treat narcolepsy and other sleep-wake disorders, adding novel mechanisms to Lilly’s research portfolio.
Lilly aims to leverage Centessa’s depth in sleep disease research to accelerate development timelines and potentially bring new sleep-wake therapeutics to market faster.
